R3 Vascular Announces $87 Million in Series B Financing
R3 Vascular will use the proceeds to support the ELITE FDA IDE pivotal trial of its best-in-class bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD.
May 9, 2024
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
R3 Vascular will use the proceeds to support the ELITE FDA IDE pivotal trial of its best-in-class bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD.